KR930021203A - 죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체 - Google Patents

죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체 Download PDF

Info

Publication number
KR930021203A
KR930021203A KR1019930005409A KR930005409A KR930021203A KR 930021203 A KR930021203 A KR 930021203A KR 1019930005409 A KR1019930005409 A KR 1019930005409A KR 930005409 A KR930005409 A KR 930005409A KR 930021203 A KR930021203 A KR 930021203A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
fibrosis
reducing
compound
doxazosin
Prior art date
Application number
KR1019930005409A
Other languages
English (en)
Other versions
KR0137927B1 (ko
Inventor
슈-밍 웡 사무엘
칼호운 스윈델 아치
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR930021203A publication Critical patent/KR930021203A/ko
Application granted granted Critical
Publication of KR0137927B1 publication Critical patent/KR0137927B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/15—Details of package parts other than the semiconductor or other solid state devices to be connected
    • H01L2924/181—Encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 포유동물의 죽상동맥경화증이 진전을 억제시키기 위한 하기 구조식(1)의 독사조신의 몇몇 히드록실화된 대사산물 및 유도체, 및 그의 약학적으로 허용가능한 산 부가염의 용도에 관한 것이다. 상기 화합물은 죽상동맥경화성 플라크에 수반되는 질환을 감소시키고, 죽상동맥경화성 플라크 성장시의 지질 침착 및 섬유증을 모두 지연 및 감소시키는데 유용하다.

Description

죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 죽상동맥경화증에 걸린 포유동물에게 죽상동맥경화성 병변 감소 또는 섬유증 억제 또는 지질 침착 억제 유효량의 하기 구조식(1) 화합물 또는 그의 약학적으로 허용가능한 산 부가염을 투여함을 포함하는, 상기 포유동물의 죽상동맥경화성 병변을 감소시키거나 또는 죽상동맥경화성 병변 진전시의 지질 침착 또는 섬유증을 억제시키는 방법.
  2. 제1항에 있어서, 상기 독사조신의 7′-히드록시 대사산물을 투여하는 방법.
  3. 제1항에 있어서, 상기 독사조신의 6′-히드록시 대사산물을 투여하는 방법.
  4. 제1항에 있어서, 상기 구조식(1)의 화합물 또는 그의 약학적으로 허용가능한 산 부가염을 경구 투여하는 방법.
  5. 제1항에 있어서, 상기 구조식(1)의 화합물 또는 그의 약학적으로 허용가능한 산 부가염을 복강내 투여하는 방법.
  6. 제1항에 있어서, 상기 구조식(1)의 화합물 또는 그의 약학적으로 허용가능한 산 부가염을 경피 투여하는 방법.
  7. 섬유증 억제 또는 지질 침착 억제 또는 죽상동맥경화성 병변 감소 유효량의 제1항에 정의된 구조식(1)의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 죽상동맥경화증에 걸린 포유동물의 죽상동맥경화 병변을 감소시키거나 또는 죽상동맥경화성 병변 진전시의 지질 침착 또는 섬유증을 억제시키기 위한 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930005409A 1992-04-01 1993-03-31 죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체 KR0137927B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86171492A 1992-04-01 1992-04-01
US861,714 1992-04-01

Publications (2)

Publication Number Publication Date
KR930021203A true KR930021203A (ko) 1993-11-22
KR0137927B1 KR0137927B1 (ko) 1998-05-15

Family

ID=25336560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930005409A KR0137927B1 (ko) 1992-04-01 1993-03-31 죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체

Country Status (17)

Country Link
US (1) US5543411A (ko)
EP (1) EP0564093B1 (ko)
JP (1) JPH0624989A (ko)
KR (1) KR0137927B1 (ko)
AT (1) ATE187069T1 (ko)
AU (1) AU660359B2 (ko)
CA (1) CA2092983C (ko)
DE (1) DE69327128T2 (ko)
DK (1) DK0564093T3 (ko)
ES (1) ES2139624T3 (ko)
GR (1) GR3032373T3 (ko)
HU (1) HU225113B1 (ko)
IL (1) IL105141A (ko)
MX (1) MX9301824A (ko)
NZ (1) NZ247307A (ko)
PT (1) PT564093E (ko)
ZA (1) ZA932307B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US20050165428A1 (en) * 2000-09-25 2005-07-28 Franco Kenneth L. Absorable surgical structure
JP2004508884A (ja) * 2000-09-25 2004-03-25 コヒージョン　テクノロジーズ，　インコーポレイテッド 再吸収可能な吻合ステントおよびプラグ
CN1826207B (zh) 2003-07-18 2010-06-16 浜松光子学株式会社 激光加工方法、激光加工装置以及加工产品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB271997A (en) * 1926-04-16 1927-06-09 Morris Engines Coventry Ltd Improvements relating to the driving of cam or other auxiliary shafts in internal combustion engines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
EP0564093B1 (en) 1999-12-01
AU660359B2 (en) 1995-06-22
CA2092983A1 (en) 1993-10-02
DK0564093T3 (da) 2000-03-27
DE69327128T2 (de) 2000-04-20
IL105141A (en) 1998-10-30
CA2092983C (en) 1996-12-31
MX9301824A (es) 1994-02-28
JPH0624989A (ja) 1994-02-01
AU3562993A (en) 1993-10-07
HU9300947D0 (en) 1993-06-28
DE69327128D1 (de) 2000-01-05
HU225113B1 (en) 2006-06-28
GR3032373T3 (en) 2000-04-27
ES2139624T3 (es) 2000-02-16
PT564093E (pt) 2000-04-28
NZ247307A (en) 1997-06-24
HUT65849A (en) 1994-07-28
IL105141A0 (en) 1993-07-08
EP0564093A1 (en) 1993-10-06
ATE187069T1 (de) 1999-12-15
US5543411A (en) 1996-08-06
KR0137927B1 (ko) 1998-05-15
ZA932307B (en) 1994-09-30

Similar Documents

Publication Publication Date Title
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
BR1100412A (pt) Composto; método para propiciar tratamento imunomodulador; e composição farmacêutica para tratamento imunomodulador
ES8608535A1 (es) Procedimiento para preparar una composicion para el tratamiento topico de acne
KR900003151A (ko) 화합물
KR900011754A (ko) (디-3급-부틸히드록시페닐)티오 유도체
KR930021203A (ko) 죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체
UA27108A1 (uk) Аhтрацикліhові глікозиди та їх фармацевтичhо прийhятhі кислотhо-адитивhі солі, спосіб їх одержаhhя, похідhі 1,6-дийод-3-оксапеhтаhу та спосіб їх одержаhhя
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
KR900018048A (ko) 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌
KR890001965A (ko) 스퍼구알린 관련 유도체
DK601683D0 (da) Dialkylaminoalkoxybenzylalkoholderivater
ES2101059T3 (es) Derivados biciclicos nitrogenados, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2118650T3 (es) Derivados de la quinolina-4-carbonilguanidina, procedimiento para la preparacion de los mismos y preparaciones farmaceuticas que contienen los compuestos.
KR900014385A (ko) 제약학적 치료
KR900012925A (ko) 인돌 유도체
KR940018351A (ko) 노나테트라에노산 유도체
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물
KR910011820A (ko) Ltb4 합성 저해제
KR910007526A (ko) 인터류킨-1 생합성 억제제로의 3-치화된-2-옥신돌 유도체
RU99118510A (ru) Композиция для лечения или предупреждения рака простаты
RU98113854A (ru) Эфирные производные транс-аповинкаминовой кислоты в качестве лекарственных средств
FR2455598A1 (fr) Nouveaux derives 5- (2- ((2,3-dihydro-1,4-benzodioxanne-2-ylmethyl)- amino)-1- hydroxyethyl)-2-hydroxybenzoiques, utiles notamment comme agents bloquants des recepteurs adrenergiques a et b, et leur procede de preparation
FI961423A0 (fi) Antrasykliinidisakkaridit, menetelmä niiden valmistamiseksi sekä niitä sisältävät farmaseuttiset koostumukset

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080110

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee